Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Twist Bioscience Corporation Common Stock

TWST

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Last trade $110.59
Day change +$5.55 (+5.28%)
Day range $102.90 – $111.43
Volume 1,028,044
Market cap $6.96B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.96B
Price / earnings
—
Price / book
15.62×
Price / sales
16.13×
EV / sales
15.89×
EV / EBITDA
-61.06×

Profitability

Earnings per share
-$2.06
Return on assets
-20.33%
Return on equity
-30.67%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.03×
Current ratio
2.67×
Quick ratio
2.38×
Cash ratio
0.98×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$98.12M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TWST, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$118.38M$110.72M$103.7M$99.01M$96.06M$92.79M$88.71M$84.71M
Cost of revenue$55.92M$53.59M$49.73M$48.17M$44.76M$46.77M$45.87M$46.48M
Gross profit$62.45M$57.12M$53.97M$50.84M$51.3M$46.03M$42.84M$38.23M
Selling, general and administrative$80.71M$76.09M$69.74M$63.76M$63.37M$63.67M$56.18M$53.14M
Research and development$18.03M$19.7M$17.13M$17.01M$18.05M$23.92M$21.31M$21.13M
Total operating expenses$98.73M$102.99M$86.87M$80.77M$81.42M$87.59M$77.48M$74.28M
Operating income-$36.28M-$45.86M-$32.9M-$29.93M-$30.12M-$41.56M-$34.64M-$36.04M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$34.74M-$43.98M-$30.25M-$26.88M$20.58M-$39.15M-$31.5M-$34.75M
Income taxes$311K$43K$253K$257K$191K$175K$97K-$96K
Net income-$35.05M-$44.02M-$30.51M-$27.14M$20.39M-$39.33M-$31.59M-$34.66M
Net income attributable to common shareholders-$35.05M-$44.02M-$30.51M-$27.14M$20.39M-$39.33M-$31.59M-$34.66M
EBITDA-$29.5M-$32.24M-$26.71M-$23.93M-$24.06M-$35.16M-$28.26M-$74.32M
Basic earnings per share-$0.56-$0.71-$0.50-$0.45$0.34-$0.66-$0.53-$0.59
Diluted earnings per share-$0.56-$0.71-$0.50-$0.46$0.33-$0.66-$0.53-$0.59

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Twist Bioscience: 3 Key Takeaways for Long-Term Investors

Twist Bioscience reported Q4 2026 revenue growth of 28% YoY to $126.6M, with AI drug discovery revenue surging 175% to $59.1M. The company achieved positive adjusted EBITDA and plans to expand its DNA synthesis capacity from 10 to 16 writers. Management expects FY2027 revenue of $550-560M (21% growth) and will reinvest profits into capacity and automation rather than seeking external funding.

Zacks Investment Research

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

ADC Therapeutics (ADCT) reported a quarterly loss of $0.16 per share, beating consensus estimates of $0.21 loss, with a 23.81% earnings surprise. Revenue of $21.72 million also exceeded expectations by 5.67%. However, the stock has declined 55.2% year-to-date versus the S&P 500's 7.8% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

The State Street SPDR S&P Biotech ETF (XBI) is reviewed as a passively managed fund with low costs (0.35% expense ratio) and $10.42 billion in assets. The ETF has delivered strong year-to-date returns of 22.76% and 12-month returns of 39.54%, though it carries high risk with a beta of 0.83 and 27.66% standard deviation. With 167 holdings and a Zacks ETF Rank of 3 (Hold), it offers diversified biotech exposure but faces competition from similar alternatives like IBB and FBT.

The Motley Fool

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.

GlobeNewswire Inc.

Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera

The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.